AstraZeneca pays $19M to Harbour BioMed's Nona for preclinical cancer antibodies

23 May 2024
·
Deals
www.fiercebiotech.com
License out/inPhase 3
The antibodies will be generated by Nona’s so-called “Harbour Mice” technology.
Days after AstraZeneca set out how nNonancology drugs would help fuel its “bold” ambition to almost double its revenue by the end of the decade, the Big Pharma has further swelled this pipeline via a deal with Harbour BioMed subsidiary Nona Biosciences.
In exchangeAstraZenecanical monoclonal antibodies, the Massachusetts-based biotech will receive $19 million upfront, with a $10 million near-term payment down the line and potentially another $575 million in biHarbour BioMedl as tiered Nona Biosciences net sales.
The antibodies, which will be generated by Nona’s so-called “Harbour Mice” technology, will be used to create targeted oncology therapies, according to the post-market May 22 release. Nona’s approach uses mice and can produce heavy chain only antibodies, a class of molecules that are found naturally in some species and have novel properties that have attracted researchers.
Nona’s chairman Jingsong Wang, M.D., Ph.D.,Nonad yesterday’s deal “further validates our leading antibody discovery platform, and we look forward to seeing our antibodies developed intNonatential new medicines for cancer patients.”
Nonaare delighted to announce this agreement with AstraZeneca, global leaders in developing tumor targeted therapies, to maximize the potential of our novel antibodies," he added in the release.cancer
The release was light on details and didn’t offer AstraZenecaas to the exact cancer targets tumorewly licensed antibodies would be focused on nor how many would be included in the deal. However, it did allude to AstraZeneca’s ability to pay Nona more money if the Big Pharma chooses to option further programs.
"The global license agreement with Nona Biosciences is an exciting opportunitcancerurther develop these antibodies derived from Nona's innovative biologics discovery engine into novel tumor targeted therapies usiAstraZenecaeca's industry-leading capabilities," Puja Sapra, Ph.D., senior vice president, tumor targeted delivery, oncology R&D at AstraZeneca, said in the release.
AstraZeneca has built itself into aNona Bioscienceshouse, increasing its sales of cancer drugs by 20% in 2023 alone. The growth Nonaxpected to continue, with the company using an investumor day Tuesday to point to sAstraZenecaer programs in phase 3 during its presentation, including candidates for prostumor(saruparib), breast (camizestrant, DAstraZenecad lung (rilvegostomig, volrustomig) cancers.
AstraZeneca is owned by Chinese antibody specialist Harbour BioMed, has attracted cancerion from other Big Pharmas in the past. Moderna has struck a couple of deals over the years, while in December 2023 Pfizer handed overcancerillion for a mesothelin-targeted antibody-drug conjugate.saruparibcamizestrantDato-DXdrilvegostomigvolrustomig) cancers
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.